The role of 177LuDotatate peptide receptor radionuclide treatment in patients with metastatic well differentiated gastroenteropancreatic neuroendocrine neoplasms (GEP-NETs)

被引：0
|
作者：
Severi, S. [1 ]
Sansovini, M. [1 ]
Ianniello, A. [1 ]
Ambrosetti, A. [1 ]
Monti, M. [1 ]
Scarpi, E. [1 ]
Di Iorio, V. [1 ]
D'Errico, V. [1 ]
Ibrahim, T. [1 ]
Paganelli, G. [2 ]
机构：
[1] IRCCS IRST, Meldola, Italy
[2] IEO, Milan, Italy
来源：
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 2013年 / 40卷
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
引用
收藏
页码：S140 / S140
页数：1
相关论文
共 50 条
  • [21] Tumor growth rate in well-differentiated G1-3 gastroenteropancreatic neuroendocrine tumors (GEP-NETs): Implications for clinical trials
    Wang, S.
    Whitman, J.
    Paciorek, A.
    Le, B. K.
    Zhang, L.
    Hope, T.
    Bergsland, E.
    JOURNAL OF NEUROENDOCRINOLOGY, 2021, 33 : 116 - 116
  • [22] Combination Systemic Therapies in Advanced Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs): A Comprehensive Review of Clinical Trials and Prospective Studies
    Diamantopoulos, Leonidas N.
    Kalligeros, Markos
    Halfdanarson, Thorvardur R.
    Diamantis, Nikolaos
    Toumpanakis, Christos
    BIOLOGY-BASEL, 2023, 12 (08):
  • [23] Tumor response in the CLARINET study of lanreotide depot vs. placebo in patients with metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
    Phan, Alexandria T.
    Dasari, Arvind
    Liyanage, Nilani
    Cox, David
    Lowenthal, Susan Pitman
    Wolin, Edward M.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
  • [24] Survival predictors of 177Lu-Dotatate peptide receptor radionuclide therapy (PRRT) in patients with progressive well-differentiated neuroendocrine tumors (NETS)
    Mina M. Swiha
    Duncan E. K. Sutherland
    Golmehr Sistani
    Alireza Khatami
    Rami M. Abazid
    Amol Mujoomdar
    Daniele P. Wiseman
    Jonathan G. Romsa
    Robert H. Reid
    David T. Laidley
    Journal of Cancer Research and Clinical Oncology, 2022, 148 : 225 - 236
  • [25] Tumor Response in the CLARINET Study of Lanreotide Depot/Autogel vs Placebo in Patients With Metastatic Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2016, 14 (03) : 11 - 12
  • [26] Survival predictors of 177Lu-Dotatate peptide receptor radionuclide therapy (PRRT) in patients with progressive well-differentiated neuroendocrine tumors (NETS)
    Swiha, Mina M.
    Sutherland, Duncan E. K.
    Sistani, Golmehr
    Khatami, Alireza
    Abazid, Rami M.
    Mujoomdar, Amol
    Wiseman, Daniele P.
    Romsa, Jonathan G.
    Reid, Robert H.
    Laidley, David T.
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2022, 148 (01) : 225 - 236
  • [27] Health resource utilization among patients with metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs) treated at a tertiary referral center.
    Meng, Jie
    Jalbert, Jessica J.
    Casciano, Roman
    Brais, Lauren K.
    Ray, David
    Pulgar, Sonia J.
    Kulke, Matthew H.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [28] Outcome analysis in patients with metastatic gastroenteropancreatic neuroendocrine tumors receiving peptide receptor radionuclide therapy with Lu-177-DOTATATE
    Pretot, Dominique
    Engel-Bicik, Ivette
    Kenkel, David
    Kaufmann, Philipp A.
    Treyer, Valerie
    Siebenhuner, Alexander R.
    JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2023, 14 (03) : 1204 - 1217
  • [29] ETCTN 10450: A phase I trial of peposertib and lutetium 177 DOTATATE in welldifferentiated somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
    Chauhan, Aman
    Kolesar, Jill
    Yan, Donglin
    Li, Daneng
    Khurana, Aman
    Carson, William Edgar
    Arnold, Susanne M.
    Gore, Steven
    Rubinstein, Larry
    Kohn, Elise C.
    Ivy, Percy
    Xiao, Ying
    Dewaraja, Yuni
    Soares, Heloisa P.
    Beumer, Jan Hendrik
    Konda, Bhavana
    Sukrithan, Vineeth
    Anthony, Lowell Brian
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : TPS658 - TPS658
  • [30] Predictors of Long-Term Outcome in Patients with Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors After Peptide Receptor Radionuclide Therapy with 177Lu-Octreotate
    Ezziddin, Samer
    Attassi, Mared
    Yong-Hing, Charlotte J.
    Ahmadzadehfar, Hojjat
    Willinek, Winfried
    Gruenwald, Frank
    Guhlke, Stefan
    Biersack, Hans-Juergen
    Sabet, Amir
    JOURNAL OF NUCLEAR MEDICINE, 2014, 55 (02) : 183 - 190
12345